Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.01.05.21268478: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Study protocol and participants: All participants gave written informed consent for sample collection according to the approval of the ethics committees of the Charité-Universitätsmedizin Berlin (EA2/010/21, EA4/188/20).
IRB: Study protocol and participants: All participants gave written informed consent for sample collection according to the approval of the ethics committees of the Charité-Universitätsmedizin Berlin (EA2/010/21, EA4/188/20).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources For flow cytometric analysis, the following fluorochrome-labeled antibodies were … SciScore for 10.1101/2022.01.05.21268478: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Study protocol and participants: All participants gave written informed consent for sample collection according to the approval of the ethics committees of the Charité-Universitätsmedizin Berlin (EA2/010/21, EA4/188/20).
IRB: Study protocol and participants: All participants gave written informed consent for sample collection according to the approval of the ethics committees of the Charité-Universitätsmedizin Berlin (EA2/010/21, EA4/188/20).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources For flow cytometric analysis, the following fluorochrome-labeled antibodies were used: CD14 (M5E2, BD Biosciences, Franklin Lakes, NJ, USA), CD3 (UCHT1, BD), CD27 (L128, BD), CD19 (SJ25C1, BD), CD24 (ML5, BD), IgD (IA6-2, BioLegend, San Diego, CA, USA), CD38 (clone HIT2, BioLegend). CD14suggested: NoneCD3suggested: (BioLegend Cat# 391501, RRID:AB_2616702)CD27suggested: NoneCD19suggested: (Agilent Cat# TC67401, RRID:AB_579635)CD24suggested: NoneIA6-2suggested: NoneCD38suggested: NoneFor labelling of surface markers, antibodies against CD3 (SK7, Biolegend), CD4 (SK3, BD), CD8 (SK1, Ebioscience, San Diego, CA, USA), CD45RO (UCHL1, BioLegend), CD62L (DREG-56, BioLegend) and PD1 (EH12.1, Becton Dickinson) were used. CD4suggested: (Cell Sciences Cat# 873.019.050, RRID:AB_10048825)CD8suggested: (Bethyl Cat# A810-007, RRID:AB_2891978)CD45ROsuggested: NoneUCHL1suggested: NoneCD62Lsuggested: NoneDREG-56suggested: NonePD1suggested: NoneSoftware and Algorithms Sentences Resources Co-expression of cytokines was quantified by Boolean gating in Flowjo. Flowjosuggested: (FlowJo, RRID:SCR_008520)Statistical analysis and graph preparation was conducted in GraphPad Prism 8 (GraphPad, La Jolla, CA, USA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:As an obvious limitation of our approach, a subgroup of patients with previous or ongoing Belatacept treatment did not benefit from MPA hold. Although patient numbers were small, our data support the notion that Belatacept efficiently inhibits vaccine responses (38) irrespective of the presence of anti-metabolites, suggesting that other approaches are needed for Belatacept-treated patients. In summary our data provide evidence that temporal hold of MPA for 5 weeks in patients under previous CNI, MPA ± CS is a viable option to accelerate and increase vaccine efficacy in KTR, particularly given that graft function remained stable and no rejection episodes or increases in anti-HLA antibodies and dd-cfDNA plasma concentrations were observed. Our study thus highlights a potential rapid vaccination strategy for at-risk patients under standard CNI-based immunosuppression that warrants testing in larger cohorts.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-